QL2401 / Qilu Pharma - LARVOL DELTA

Safety, Tolerability, PK, PD, and Immunogenicity of QL2401 in Healthy Chinese Adults (clinicaltrials.gov) - P1 | N=71 | Completed | Sponsor: Qilu Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Completed | Trial completion date: Dec 2026 ➔ Jun 2026

First-in-human • Trial completion • Trial completion date • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis